ClinicalTrials.gg
RecruitingNCT07619092FLEETUpdated Jun 1, 2026

Flumazenil for Benzodiazepine Reversal in Electroconvulsive Therapy

An interventional study of Flumazenil and Electroconvulsive therapy (ECT) in Depression - Major Depressive Disorder, Bipolar Disorder (BD) and Functional Magnetic Resonance Imaging (fMRI), sponsored by Anders Jørgensen. Recruiting at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by Anders Jørgensen · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
145
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies in Bipolar Disorder with a site in Denmark — 13 open to participants now, 17 under way, 1 of them phase 3. Bipolar Disorder · Denmark.

Planned enrollment
21st of 42
145 · median 134
Started
2026
with 1 other
No phase
30 of 49
6 open now
Primary completion
2028-08
later than 15 of 16 live
Registered
45th of 49
by date
Lead sponsor
1 of 49
Anders Jørgensen

Among the 49 studies in Bipolar Disorder with a site in Denmark, this one is the 21st largest by planned enrollment of the 42 interventional ones that give a count, is one of 2 that started in 2026, is one of 30 with no phase, reaches primary completion later than 15 of the 16 other live ones, and was the 45th registered.

Bipolar Disorder

1,687 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

13 of the 49 studies in Bipolar Disorder with a site in Denmark are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 207 Bipolar Disorder studies recruiting now, 60 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Bipolar Disorder with a site in Denmark, or all of them as a file.
02

Study summary

The goal of this study is to investigate whether administering flumazenil to reverse the effects of benzodiazepines and/or zopiclone during electroconvulsive therapy (ECT) can help reduce cognitive side effects without diminishing treatment effectiveness in hospitalized patients with depression.

The investigators hypothesize that blockade of the GABA receptor with flumazenil will reduce cognitive side effects through improved seizures and a reduced need for electrical charge escalation during the ECT series. Cognitive side effects will be measured by the total score on the Screening for Cognitive Impairment in Psychiatry (SCIP) (primary outcome) at follow-up after completion of the ECT series. Furthermore, it is expected that the flumazenil strategy will reduce pre-treatment anxiety and improve patient satisfaction (secondary outcomes). In addition, flumazenil strategy is hypothesized to have beneficial effects on subjective cognitive complaints, autobiographical memory, and executive functioning (secondary outcomes). Finally, the flumazenil strategy is expected to be associated with more favorable structural and functional changes in executive functioning and memory-related brain networks after completion of the ECT series, which may, in turn, be linked to better overall cognition and autobiographical memory (secondary outcome measures). For exploratory purposes, the study will also examine longitudinal changes in depressive symptoms and cognitive outcomes from baseline to follow-up (tertiary outcomes).

Investigators will compare two different pre-ECT benzodiazepine management strategies:

  1. Flumazenil strategy (experimental): continued benzodiazepine and/or zopiclone use up until the time of the ECT session, followed by administration of flumazenil immediately prior to ECT
  2. Benzodiazepine withholding strategy (treatment as usual):

discontinuation of benzodiazepines and/or zopiclone prior to the ECT in accordance with standard clinical practice

Read the detailed description

The study will include adult inpatients (≥18 years of age) diagnosed with a mood disorder (major depressive disorder or bipolar disorder), currently experiencing a depressive episode (ICD-10: F31.3-5, F32 or F33), who are deemed eligible for ECT by a treating psychiatrist who is not affiliated with the study. Based on a power analysis, 132 participants (66 per group) are required to achieve adequate statistical power. To account for an anticipated 10% dropout rate from baseline to follow-up, the investigators will recruit 145 participants. Recruitment will be carried out through psychiatric hospital wards within the Mental Health Services of the Capital Region of Denmark.

Participants will be randomized following an initial screening to confirm eligibility. Randomization will be conducted using the automated randomization module in the Research Electronic Data Capture (REDCap) system, based on a pre-generated randomization list with variable block sizes of two and four. Allocation will be stratified by age (\< 60 or ≥ 60 years) and electrode placement (unilateral vs. bilateral). Randomization will occur no later than the day prior to the second ECT session of the treatment series. Primary outcome assessors are blinded to the group allocation.

Baseline assessments will be conducted the day before the first ECT session or, if not otherwise possible, the day before the second ECT session. Participants will complete a brief neuropsychological assessment comprising the Screen for Cognitive Impairment in Psychiatry (SCIP) and additional measures of executive functioning and autobiographical memory. Participants will also complete self-report questionnaires assessing subjective cognitive complaints. Depressive symptom severity will be rated using the Hamilton Depression Rating Scale (HDRS).

During the ECT treatment series, repeated assessments will be conducted for each session. Participants will provide self-reported ratings of pre-treatment anxiety shortly before the session, while clinicians will record measures of seizure architecture, and time to reorientation following the session.

Follow-up assessments will be conducted 3-7 days after completion of the ECT-series, which serves as the primary end point. At follow-up, the brief neuropsychological assessment, self-report questionnaires, and HDRS ratings will be repeated. Participants will also complete a short self-report questionnaire of their treatment satisfaction. Structural and functional magnetic resonance imaging (MRI) is conducted within the 3-7 days after completion of the ECT series, coinciding with the follow-up assessment.

03

Conditions studied

  • Depression - Major Depressive Disorder
  • Bipolar Disorder (BD)
  • Functional Magnetic Resonance Imaging (fMRI)
  • Cognition
  • Autobiographical Memory
  • Electroconvulsive Therapy
  • ECT
  • Treatment Outcome
  • Inpatients

Keywords

  • flumazenil
  • benzodiazepine reversal
  • electroconvulsive therapy
  • randomized controlled trial
  • functional magnetic resonance imaging
  • Autobiographical Memory Test (AMT)
  • Inpatients
  • Major Depressive Disorder
  • Bipolar Disorder
  • Treatment Outcome
  • Cognition
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Current depressive episode (unipolar or bipolar), corresponding to ICD-10 codes F31.3-5, F32 or F33.
  • Admitted at a study affiliated department in the Mental Health Services of the Capital Region of Denmark
  • Referred to ECT by the regular psychiatrist and has given consent to ECT
  • Currently receiving treatment with a benzodiazepine and/or zopiclone, at a minimum daily dose equivalent to 0.5 mg lorazepam.

Exclusion criteria

Exclusion criteria:

  • Involuntary treatment with ECT
  • Known gross abnormalities in brain structure deemed likely to influence cognitive functioning
  • Pregnancy or breast-feeding
  • Inability to read or understand Danish
  • Acute organic brain disease (e.g., delirium) influencing the ability to give
  • Any pre-existing condition associated with an increased risk of prolonged or uncontrollable seizures, including but not limited to epilepsy or alcohol- or benzodiazepine withdrawal states
  • Conditions associated with reduced metabolism of flumazenil (e.g., liver failure)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
145 participants (estimated)

Study arms

  • Experimental
    Flumazenil for benzodiazepine reversal

    Participants continue benzodiazepine and/or zopiclone treatment up until the ECT session, receiving flumazenil to reverse their effects

    Drug: Flumazenil

  • Active comparator
    Treatment as usual (benzodiazepine hold)

    Participants discontinue benzodiazepine and/or zopiclone treatment the day prior to the ECT session.

    Procedure: Electroconvulsive therapy (ECT)

Interventions

  • The intervention involves continuation of benzodiazepine and/or zopiclone treatment up to the time of ECT, followed by administration of flumazenil immediately prior to anesthesia to transiently reverse the effect of benzodiazepines and/or zopiclone. Otherwise, ECT is administered according to standard clinical procedures.

  • ProcedureElectroconvulsive therapy (ECT)

    Standard ECT treatment performed in accordance with clinical practice, with benzodiazepines and/or zopiclone withheld after 5:00 p.m. on the day before each session

06

What researchers measure

Primary outcomes

  1. Screen for Cognitive Impairment in Psychiatry (SCIP)

    The primary outcome measure is the total score on the SCIP at follow-up (post-ECT). The SCIP is a brief neuropsychological assessment tool designed to detect cognitive deficits in individuals with psychotic and affective disorders. It comprises five subtests assessing key cognitive domains: verbal learning and memory (VLT-I and VLT-D), working memory (WMT), verbal fluency (VFT), and processing speed (PST). The total score provides a broad indicator of overall cognitive functioning. Higher scores mean a better outcome.

    Time frame: Baseline (the day before the first or second session in the ECT series) and follow-up (3-7 days after completion of the ECT series)

Secondary outcomes

  1. Hamilton Depression Rating Scale (HDRS)

    Clinician-administered depression assessment scale of 17 items. Score range: 0-52. Clinical response at follow-up (primary endpoint) is assessed using the HAM-D6 subscale, collectively comprising the core symptoms of depression with score range: 0-22. Higher scores mean a worse outcome.

    Time frame: Baseline (the day before the first or second session in the ECT series) and follow-up (3-7 days after completion of the ECT series)

  2. Cognitive Complaints in Bipolar Disorder Rating Scale (COBRA)

    Self-report questionnaire assessing subjective cognitive complaints. Score range: 0-48. Higher scores mean a worse outcome.

    Time frame: Baseline (the day before the first or second session in the ECT series) and follow-up (3-7 days after completion of the ECT series)

  3. Squire Subjective Memory Questionnaire (SSMQ)

    Self-report questionnaire assessing subjective memory complaints. Score range: -72 - +72. Higher (more positive) scores mean a better outcome.

    Time frame: Baseline (the day before the first or second session in the ECT series) and follow-up (3-7 days after completion of the ECT series)

  4. Autobiographical Memory Test (AMT)

    Neuropsychological instrument used to assess the ability to retrieve autobiographical memories and their specificity. Higher scores mean a better outcome.

    Time frame: Baseline (the day before the first or second session in the ECT series) and follow-up (3-7 days after completion of the ECT series)

  5. Trail Making Test B (TMT-B)

    Neuropsychological test assessing executive function. Scored by time to completion. Higher scores mean a worse outcome.

    Time frame: Baseline (the day before the first or second session in the ECT series) and follow-up (3-7 days after completion of the ECT series)

  6. Verbal learning and memory (VLT-I)

    SCIP subtest assessing verbal learning and immediate recall. Score range: 0-30. Higher scores mean a better outcome.

    Time frame: Baseline (the day before the first or second session in the ECT series) and follow-up (3-7 days after completion of the ECT series)

  7. Delayed verbal recall (VLT-D)

    SCIP subtest assessing delayed verbal recall. Score range: 0-10. Higher scores mean a better outcome.

    Time frame: Baseline (the day before the first or second session in the ECT series) and follow-up (3-7 days after completion of the ECT series)

  8. Working memory test (WMT)

    SCIP subtest assessing working memory capacity. Score: 0-24. Higher scores mean a better outcome.

    Time frame: Baseline (the day before the first or second session in the ECT series) and follow-up (3-7 days after completion of the ECT series)

  9. Verbal fluency test (VFT)

    SCIP subtest assessing verbal fluency. No score range. Higher scores mean a better outcome.

    Time frame: Baseline (the day before the first or second session in the ECT series) and follow-up (3-7 days after completion of the ECT series)

  10. Processing speed test (PST)

    SCIP subtest assessing processing speed. Score range: 0-30. Higher scores mean a better outcome.

    Time frame: Baseline (the day before the first or second session in the ECT series) and follow-up (3-7 days after completion of the ECT series)

  11. Patient Satisfaction Survey (PSS)

    Self-report questionnaire assessing patient satisfaction following ECT treament. A subset of items are used. Higher scores mean a better outcome.

    Time frame: Follow-up (3-7 days after completion of the ECT series)

  12. Visual Analogue Scale for Anxiety (VAS-A)

    Visual analogue self-report scale assessing anxiety severity within the last 24 hours. Score range: 0-100. Higher scores mean a worse outcome.

    Time frame: Per ECT session

  13. Time to reorientation

    Clinician-administered structured interview measuring time to reorientation (in minutes) according to Sobin et al. (1995) and Stuiver et al. (2024). Patients are screened every 5 minutes after EEG-offset for orientation in five domains: name, location, age, date of birth, and day of the week. Reorientation is defined as the time in minutes from EEG-offset until the patient provides at least 4 out of 5 correct answers. If the patient fails to reach reorientation within 60 minutes, a score of 70 minutes is registered. Higher scores indicate a longer recovery period and a worse outcome.

    Time frame: Per ECT session

  14. Seizure quality

    Clinician-rated categorical EEG classification of seizure quality (A, A-T, T, O, S). A-seizures represent the optimal therapeutic pattern.

    Time frame: Per ECT session

  15. Seizure length (EEG)

    EEG seizure duration (seconds) from the end of stimulation to the last unequivocal ictal discharge. Continuous physiological measure.

    Time frame: Per ECT session

  16. Stimulus dose

    Stimulus dose recorded as the percentage of the device's maximum output (%) delivered during each treatment, as displayed on the ECT device readout. Range: 0-200%.

    Time frame: Per ECT session

  17. Prefrontal and medial temporal activation during autobiographical memory retrieval

    Functional magnetic resonance imaging (fMRI) measure of brain activity during an autobiographical memory test

    Time frame: Follow-up (3-7 days after completion of the ECT series)

  18. Prefrontal, parietal and medial temporal activation during memory encoding

    Functional magnetic resonance imaging (fMRI) measure of brain activity during a memory encoding task

    Time frame: Follow-up (3-7 days after completion of the ECT series)

  19. Prefrontal and parietal activation during spatial N-back

    Functional magnetic resonance imaging (fMRI) measure of brain activity during a working memory task

    Time frame: Follow-up (3-7 days after completion of the ECT series)

07

Study locations

1 of 1 sites recruiting
  • Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
    Frederiksberg, Capital Region 2000, Denmark
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Aug 2028, 31 months after the start.

Of 361 non-industry interventional studies with no phase under Bipolar Disorder, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 58. This study's planned 31 months is below that.

Counting every sponsor, half of 363 studies reached it within 37 months; a quarter within 23 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2025
First posted
Jun 1, 2026
StartActual
Jan 15, 2026
Primary completionEst.
Aug 2028
CompletionEst.
Aug 2028
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07619092
Lead sponsor
Anders Jørgensen
Responsible party
Anders Jørgensen (Consultant psychiatrist and clinical research associate professor, Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital) — Sponsor-investigator
First posted
Jun 1, 2026
Start date
Jan 15, 2026
Primary completion
Aug 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
Jun 1, 2026

Study contacts

Stella K. S. Lystlund, MSc in Psychology
Contact
stella.klara.soerensdottir.lystlund@regionh.dk
+ 45 21 35 40 55
Yunus Kiros, MD
Contact
yunus.kiros.02@regionh.dk
+ 45 81 71 95 29
Anders Jørgensen, MD, Ph.D.
principal investigator · Mental Health Services of the Capital Region

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Flumazenil

Start the discussion